MGBlab：微生物领域的“贝尔实验室”

Core Viewpoint - MGBlab is leading a paradigm revolution in global micro-ecological health by reconstructing health interventions through the microbiome, focusing on the gut-brain axis and leveraging proprietary technologies and industry standards [1] Group 1: Research and Innovation - MGBlab positions itself as a "microbial medical innovation engine" by reconstructing the underlying rules of the industry through patented technology and industry standards [2] - The company has developed a high-throughput anaerobic single-cell screening platform that enhances strain selection efficiency by 10,000 times compared to traditional methods [2] - The WisMarker model advances research from correlation to causation in linking gut microbiota with health issues such as developmental disorders and mental health conditions [2] Group 2: Value Standards and Industry Standards - MGBlab has drafted the world's first standard for high-throughput sequencing interpretation of human gut microbiota, filling a gap in China's microbiome detection standardization [3] - The company is the primary drafting unit for the "Probiotic Preparations Food" group standard, establishing technical requirements and quality control systems for probiotic products [3] - The AI-driven Cross-Feeding Probiotics (CFP) platform enhances strain survival and colonization efficiency by over 30% [3] Group 3: Clinical Research and Patents - MGBlab collaborates with prestigious institutions to conduct clinical trials, replacing empirical methods with a three-dimensional evidence chain [4] - The company has secured over 40 patents, reinforcing its research barriers and technological capabilities [5] - The WisMarker model integrates over 500,000 clinical samples and gut metagenomic data, achieving predictive accuracy at an internationally advanced level [6] Group 4: Technological Framework - MGBlab's IMM platform has identified thousands of maternal strains, addressing gut compatibility issues for the Chinese population [7] - The SMART platform provides systematic microbiome assessment and reconstructive therapy, creating a closed-loop system of resources, technology, and application [10] Group 5: Strategic Development - MGBlab's "10-2-1 China Maternal Strain Initiative" aims to localize technology and reduce reliance on foreign strains, which currently dominate 85% of the Chinese infant probiotic market [11] - The initiative is supported by over 2,000 strain selection experiments daily and more than 19 clinical studies annually, demonstrating a commitment to practical advancements [12] - The company's efforts are redefining the global infant micro-ecological intervention landscape through localized strain development [12]